^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Hepatocellular Carcinoma….First-Line Systemic Therapy….Useful in Certain Circumstances...Nivolumab + ipilimumab added as a category 2B recommendation for TMB-H tumors.
